Category: Disease Prevention & Management

New clinical evidence presented at the ENDO 2026 annual meeting suggests a paradigm shift in the management of postmenopausal health, revealing that women who utilize menopausal hormone therapy (MHT) face a substantially lower risk of developing low bone mineral density (BMD) compared to those who do not. The study, led by Diego Espinoza-Peralta, MD, MSc,…

The Endocrine Society officially concluded its annual meeting, ENDO 2026, this past June, drawing thousands of clinicians, researchers, and industry professionals to the McCormick Place convention center in Chicago, Illinois. As one of the world’s most significant gatherings for the endocrine community, the conference served as a pivotal platform for unveiling cutting-edge research in metabolic…

The Endocrine Society’s annual meeting, ENDO 2026, concluded this June in Chicago, marking a pivotal moment for a field navigating a landscape of shifting healthcare priorities and fluctuating research funding. Hosted in a city synonymous with transformation and the evolution of jazz, the conference served as a testament to the resilience of endocrinologists who continue…

The Endocrine Society has announced the formal launch of its Center on Obesity, a comprehensive digital and strategic hub designed to centralize research, clinical guidance, and advocacy efforts. This initiative arrives alongside the publication of a major new Scientific Statement titled "Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines." Led…

The Endocrine Society, a global leader in the field of endocrinology and metabolism, has announced the official launch of its new Center on Obesity, a strategic initiative designed to consolidate scientific expertise and address the burgeoning global health crisis of obesity. This significant milestone will be marked by a high-profile virtual event on September 9,…

The United States Food and Drug Administration (FDA) has ushered in a transformative era for both oncology and cardiometabolic medicine with two landmark approvals issued during the final week of August. On August 26, the agency granted approval to Rasonque (daraxonrasib), a first-in-class targeted therapy for metastatic pancreatic adenocarcinoma, a disease long considered one of…

A New Frontier in Obesity Therapeutics: Adipose-Targeted RNAi The current landscape of obesity treatment is dominated by GLP-1 and GIP receptor agonists, which primarily function by suppressing appetite and slowing gastric emptying. While highly effective, these therapies often result in significant loss of lean muscle mass and require frequent administration. Moonwalk Biosciences is charting a…

The Endocrine Society’s annual ENDO 2026 conference, held this year in Chicago, Illinois, served as a premier global stage for the latest advancements in hormone research and clinical practice, highlighting the critical contributions of early-career investigators. Among the most anticipated segments of the conference was the Rising Star Power Talks, a high-stakes, "blitz-style" research communication…

The Endocrine Society has officially announced that Bradley David Anawalt, MD, a distinguished professor and vice chair in the Department of Medicine at the University of Washington School of Medicine, has been named the recipient of the 2026 Outstanding Educator Laureate Award. This prestigious recognition, part of the Society’s annual Laureate Awards program, celebrates Dr.…

The Endocrine Society, a leading global organization representing thousands of physicians and scientists specializing in hormone research and clinical care, formally announced its support today for the introduction of the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act in the U.S. House of Representatives. This bipartisan legislative effort, spearheaded by a coalition…